Effect of SLC01B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-Lndependent prostatic cancer

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3312-3318

  Hamada, Akinobu ^a,h   Sissung, Tristan ^b   Price, Douglas K ^a   Danesi, Romano ^g   Chau, Cindy H ^a   Sharifi, Nima ^a   Venzon, David ^d   Maeda, Kenji ^e   Nagao, Keisuke ^f   Sparreboom, Alex ^b   Mitsuya, Hiroaki ^e,i   Dahut, William L ^c   Figg, William D ^a,b,c,f  

^a Laboratory of Molecular Pharmacology   (United States)

^b Clinical Research Core   (United States)

^c Medical Oncology Branch   (United States)

^d Biostatistics and Data Management Section   (United States)

^e Experimental Retrovirology Section

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF PISA   (Italy)

^h Department of Clinical Pharmaceutical Sciences ^*  (Japan)

ⁱ KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GUANINE; ORGANIC ANION TRANSPORTER; PROTEIN OATP1B3; TESTOSTERONE; UNCLASSIFIED DRUG; SLCO1B3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; GENE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HORMONE TRANSPORT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B3 GENE; SURVIVAL TIME; ANIMAL; CAUCASIAN; CELL STRAIN COS1; CERCOPITHECUS; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; SITE DIRECTED MUTAGENESIS;

ADULT; AGED; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUORESCENT ANTIBODY TECHNIQUE; HAPLOTYPES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; TESTOSTERONE; TRANSFECTION;

EID: 50349085911     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4118     Document Type: Article

References (41)

1. Haiman CA, Stampfer MJ, Giovannucci E, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001;10:743-8.
2. Imamoto T, Suzuki H, Akakura K, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001;48:573-8.
3. Kakinuma H.Tsuchiya N, Habuchi T, et al. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. Prostate Cancer Prostatic Dis 2004;7:333-7.
4. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33.
5. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst1986;76:45-8.
6. Soloway MS, Ishikawa S, van der Zwaag R.Todd B. Prognostic factors in patients with advanced prostate cancer. Urology1989;33:53-6.
7. Titus MA, Schell MJ, Lih FB.Tomer KB, Mohler JL Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
8. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev1997;6:967-9.
9. Ntais C, Polycarpou A, loannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:120-6.
10. Tsuchiya N, Wang L, Suzuki H, et al. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 2006;24:1982-9.
11. Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120:1689-99.
12. Cui Y, Konig J, Nies AT, et al. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (0ATP8) in liver and hepatocellular carcinoma. Lab Invest 2003;83:527-38.
13. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275:23161-8.
14. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278:G156-64.
15. SekineT, Miyazaki H, Endou H, Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol 2006;290:F251 -61.
16. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters 0ATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429-45.
17. Letschert K, Keppler D, Konig J. Mutations in the SLC01B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14:441-52.
18. Smith NF, Marsh S, Scott-HortonTJ, et al. Variants in the SLC01B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82.
19. Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 2006;21:165-9.
20. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006;372:432-43.
21. Figg WD, Liu Y Arlen P, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005; 173:790-6.
22. Bowden CJ, Figg WD, Dawson NA, et al. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol 1996;39:1-8.
23. Dawson N, Figg WD, Brawley OW, et al. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Clin Cancer Res 1998;4:37-44.
24. Dawson NA, Figg WD, Cooper MR, et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997;15:1470-7.
25. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2532-9.
26. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-93.
27. Efron B.Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
28. Vesovic Z, Herkommer K, Vogel W, Paiss T, Maier C. Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. Anticancer Res 2005;25:1303-7.
29. Powell IJ, Zhou J, Sun Y, et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 2004;172: 1848-52.
30. Cicek MS, Liu X, Casey G.Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11 α in prostate cancer risk and aggressiveness Cancer Epidemiol Biomarkers Prev 2005;14:2173-7.
31. Gsur A, Feik E, Madersbacher S. Genetic polymorphisms and prostate cancer risk. World J Urol 2004; 21:414-23.
32. Keppler D, Konig J, Cui Y. The human hepatocyte-specific organic anion transporter encoded by the SLC21A8 gene. Gastroenterology 2002; 122:1545 - 6; author reply 6.
33. Cui Y Konig J, Leier I, Buchholz U, Keppler D Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001,276:9626-30.
34. Isern J, Hagenbuch B, Stieger B. Meier PJ, Meseguer A. Functional analysis and androgen-regulated expression of mouse organic anion transporting polypeptide 1 (Oatp1) in the kidney. Biochim Biophys Acta 2001; 1518:73-8.
35. Lu R, Kanai N, Bao Y, Wolkoff AW, Schuster VL. Regulation of renal oatp mRNA expression by testosterone. Am J Physiol 1996;270:F332-7.
36. Roche PJ. Hoare SA, Parker MG. A consensus DNA-binding site for the androgen receptor. Mol Endocrinol 1992;6:2229-35.
37. Sharifi N, GulleyJL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294: 238-44.
38. Mostaghel EA, Montgomery RB, Lin DW.The basic biochemistry and molecular events of hormone therapy. Curr Urol Rep 2007;8:224-32.
39. Gregory CW, Johnson RT. Jr., Mohler JL. French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Res 2001:61 2892-8
40. Stanbrough M, Bubley GJ. Ross K, et al Increased expression of genes convening adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 2006:66:2815-25
41. Sharifi N, Hamada A, Sissung T, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008; in press.